| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | October 28, 2024 9:00 A.M. |
| Form: | F-6 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/11/2024 | Buy → Underperform | Jefferies | |
| 8/29/2023 | Buy → Hold | HSBC Securities | |
| 5/18/2023 | Outperform → Mkt Perform | Bernstein | |
| 3/17/2023 | Neutral → Buy | BofA Securities | |
| 1/30/2023 | Underweight | JP Morgan | |
| 11/14/2022 | Neutral → Underperform | Credit Suisse | |
| 1/3/2022 | Neutral | BofA Securities | |
| 11/1/2021 | $78.00 → $80.00 | Overweight | Barclays |
Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY)) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q4FY24 FY24 Revenues ₹ 70,830 Mn [Up: 12% YoY; Down: 2% QoQ]^ ₹ 279,164 Mn [Up: 14% YoY]^ Gross Margin 58.6% [Q4FY23: 57.2%; Q3FY24: 58.5%] 58.6% [FY23: 56.7%] SG&A Expenses ₹ 20,476 Mn [Up: 14% YoY; 1% QoQ] ₹ 77,201 Mn [Up: 13%
Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as ", Dr. Reddy', s", )), today announced that it has acquired MenoLabs® business, a leading women's health and dietary supplement branded portfolio from Amyris, Inc. ("Amyris") in Amyris' Chapter 11 sales process. Dr. Reddy's acquired the entire MenoLabs supplements portfolio which includes seven branded products designed to provide health support and address symptoms of perimenopause and menopause. Brands include MenoFit™ and MenoGlow™ probiotics, Happy Fiber™ and Well Rested™ dietary supplements, Athena's Shield™ menopause support supplement, and Goodn
Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY)) today announced its consolidated financial results for the quarter ended Sep 30, 2023. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Revenues Rs. 68,802 Mn [Up: 9% YoY; Up: 2% QoQ] Gross Margin 58.7% [Q2 FY23: 59.1%; Q1 FY24: 58.7%] SG&A Expenses Rs. 18,795 Mn [Up: 13% YoY; 6% QoQ] R&D Expenses Rs. 5,447 Mn[7.9% of Revenues] EBITDA Rs. 21,813 Mn [31.7% of Revenues] Profit before Tax Rs. 19,134 Mn [Up: 19% YoY; Up: 4% QoQ]
On Wednesday, Haleon plc (NYSE:HLN) agreed to sell its nicotine replacement therapy business outside of the U.S. to Dr. Reddy's Laboratories SA, a wholly owned subsidiary of Dr. Reddy's Laboratories Limited (NYSE:RDY) for 500 million pounds (around $632 million). The nicotine replacement therapy (NRT) portfolio consists of brands such as Nicotinell, Nicabate, Habitrol, and Thrive, which are available in gum, lozenge, and patch forms across over 30 markets. The 500 million pound consideration is structured as an upfront cash payment of 458 million pounds, with a further up to 42 million pounds deferred performance-based consideration payable during 2025 and H1 2026. The transaction
Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's") has been ranked among the top employers according to the 2024 Top Biotech and Pharma Employers Survey conducted by Science. This marks the third consecutive appearance of Dr. Reddy's in the list. In 2022, Dr. Reddy's entered the prestigious list at rank 18. In 2023, the company was placed at number 16. In the latest 2024 rankings, Dr. Reddy's is placed at number 15 with high scores in ‘Employee Respect', ‘Employee Loyalty' and ‘Social Responsibility'. The full list is available here: https://www.science.org/content/article/top-20-2024-who-did-science-readers-select-best-biopharma The prestigious Science magazine is a U.S.-based peer-reviewed a
Dr. Reddy's Laboratories Inc., the U.S. arm of Dr. Reddy's Laboratories Ltd., a global pharmaceutical company headquartered in Hyderabad, India, today announced the launch of a comprehensive employee support program focused on menopause awareness, benefits, and training, in alignment with Menopause Awareness Month this October. This initiative underscores the company's commitment to fostering an inclusive and supportive work environment by addressing the unique needs of its employees who are and will experience menopause. "As a company deeply invested in the well-being of our employees, we recognize that menopause is a significant phase in many of our employees' lives," says Ashish Girotra
Aurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy's Laboratories Limited and a clinical stage biotech committed to bringing in novel and effective therapeutics for the treatment of cancer, has announced the Phase 1 results for Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study – India's first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma. The study reported initial results from the first 8 patients. All patients were heavily pre-treated with median of 5.5 previous lines of treatment. Most patients had also received transplant in the past and had disease progression post-transplant. All 8 patient
Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as ", Dr. Reddy', s", )), today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America, and member of the Management Council. As part of the Dr. Reddy's senior leadership team, he will be responsible for the company's North America business and will be based out of the Princeton, New Jersey, U.S. office. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528120424/en/Milan Kalawadia (Photo: Business Wire) "I am excited to start this next chapter in my journey at Dr
Jefferies downgraded Dr. Reddy's from Buy to Underperform
HSBC Securities downgraded Dr. Reddy's from Buy to Hold
Bernstein downgraded Dr. Reddy's from Outperform to Mkt Perform
6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)
EFFECT - DR REDDYS LABORATORIES LTD (0001135951) (Filer)
6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)
SC 13D/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)
SC 13D/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)
SC 13G/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)